Leo Cancer Care, a Horley, UK-based company developing medical devices, raised an undisclosed amount in Series C funding.
Backers included McLaren Health Care Corporation, Cone Health, Wisconsin Alumni Research Foundation, Macmillan Cancer Support and Aviko Radiopharmaceuticals.
The company intends to use the funds to expand into the Asian markets, particularly in Singapore, Japan, and South Korea, where they have begun building teams and establishing a commercial presence.
Led by CEO Stephen Towe, Leo Cancer Care is a radiation therapy company providing a family of products that can provide a streamlined and efficient treatment while making the patient feel in control. The upright patient positioning and CT imaging system, named Marie®, utilizes a fixed radiation beam with patients rotated slowly and smoothly to different beam angles as treatment is administered. Marie® removes the need for a gantry while still providing 360 degrees of beam angles. This gantry-less approach enables a significant reduction in spatial footprint and cost, particularly for proton therapy and carbon ion therapy. The solution allows patients to remain in an upright position during treatment.
Commenting on the news, Stephen Towe said: “This funding marks an important milestone, as it will enable the growth of our business and allow us to build the necessary infrastructure to support our system once it is installed at various sites. The investment will also help us to build a global footprint.”
FinSMEs
13/06/2024